Head-To-Head Review: ImmunoPrecise Antibodies (NASDAQ:IPA) & Inspire Medical Systems (NYSE:INSP)

Inspire Medical Systems (NYSE:INSP) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk.

Valuation and Earnings

This table compares Inspire Medical Systems and ImmunoPrecise Antibodies”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspire Medical Systems	$802.80 million	2.84	$53.51 million	$1.73	44.55
ImmunoPrecise Antibodies	$17.59 million	5.50	-$21.69 million	($0.68)	-3.08

Inspire Medical Systems has higher revenue and earnings than ImmunoPrecise Antibodies. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Inspire Medical Systems and ImmunoPrecise Antibodies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspire Medical Systems	0	7	7	0	2.50
ImmunoPrecise Antibodies	0	0	2	0	3.00

Inspire Medical Systems presently has a consensus target price of $154.43, indicating a potential upside of 100.37%. ImmunoPrecise Antibodies has a consensus target price of $4.00, indicating a potential upside of 90.93%. Given Inspire Medical Systems’ higher possible upside, analysts clearly believe Inspire Medical Systems is more favorable than ImmunoPrecise Antibodies.

Risk and Volatility

Inspire Medical Systems has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, ImmunoPrecise Antibodies has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.

Insider and Institutional Ownership

94.9% of Inspire Medical Systems shares are owned by institutional investors. Comparatively, 6.7% of ImmunoPrecise Antibodies shares are owned by institutional investors. 2.3% of Inspire Medical Systems shares are owned by company insiders. Comparatively, 6.8% of ImmunoPrecise Antibodies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Inspire Medical Systems and ImmunoPrecise Antibodies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inspire Medical Systems	6.17%	10.38%	8.93%
ImmunoPrecise Antibodies	-122.10%	-40.62%	-22.19%

Summary

Inspire Medical Systems beats ImmunoPrecise Antibodies on 11 of the 14 factors compared between the two stocks.

About Inspire Medical Systems

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.